To cast light on the possible non-myeloma functions or origins of the p52-bound regulatory elements classified as de novo enhancers, we examined the activity of these loci across the Roadmap Epigenomics collection which encompasses a diverse array of tissue types. Here, NFKB2 is linked to plasma cell myeloma.